Lantheus Announces Presentation of Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Lantheus Holdings, Inc., a leading radiopharmaceutical company, announced that it will be presenting new clinical data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. The data includes a Phase 1/2 study evaluating LNTH-2403, a novel LRRC15-targeted radiopharmaceutical, in relapsed/refractory osteosarcoma patients, along wit…